Tüdőrák: vizsgálatok itt: Spanyolország
275 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 17.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Where
- A Coruna, Badajoz, Badalona, Barakaldo, Barcelona, Burgos, Girona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Lugo, Madrid, Málaga, Marbella, Oviedo, Santander, Sevilla, Valencia, Valladolid, Zaragoza
- Életkor
- 18 év and over
- People
- 780 worldwide
- Run by
- Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00 - 2. fázisTaking peopleA Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 182 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06855771 · EU 2024-519814-29-00 - 1/2. fázisTaking peopleA Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
- Where
- Badajoz, Badalona, Barcelona, Girona, Madrid, Manresa, Seville, Valencia
- Életkor
- 18 év and over
- People
- 118 worldwide
- Run by
- MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07407933 - 1. fázisNot yet taking people in SpanyolországA phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
- Where
- Barcelona, L'Hospitalet de Llobregat
- Életkor
- 18 év and over
- People
- 62 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521702-18-00 - 3. fázisTaking peoplePhase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
- Where
- A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Valencia
- Életkor
- 18 év and over
- People
- 168 worldwide
- Run by
- Amgen Inc.
See details and how to join2026-525489-23-00 - No phaseTaking peopleORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Where
- A Coruña, Barcelona, Girona, Las Palmas de Gran Canaria, Madrid, Málaga, Sabadell, Santiago de Compostela, Valencia
- Életkor
- 18 év and over
- People
- 2285 worldwide
- Run by
- Guardant Health, Inc.
See details and how to joinNCT05059444 - 1/2. fázisTaking peopleA Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
- Where
- Madrid
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07325136 · EU 2025-524090-16-00 - No phaseTaking peopleComparison of Biportal Versus Multiportal Robotic Approaches for Pulmonary Resection in NSCLC
- Where
- L'Hospitalet de Llobregat
- Életkor
- 18 év and over
- People
- 80
- Run by
- Carlos Déniz
See details and how to joinNCT07818135 - 1/2. fázisTaking peopleFirst in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06657222 · EU 2025-522517-35-00 - 1. fázisTaking peopleA Phase 1/1b Study of IAM1363 in HER2 Cancers
- Where
- Barcelona, Madrid, Málaga, Seville, Valencia
- Életkor
- 18 év and over
- People
- 383 worldwide
- Run by
- Iambic Therapeutics, Inc
See details and how to joinNCT06253871 - 2. fázisTaking peopleRepotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
- Where
- Alicante, Barakaldo, Barcelona, Elche, Girona, León, Lugo, Madrid, Murcia, Oviedo, Pamplona, Reus, Sabadell, Santiago de Compostela, Valencia
- Életkor
- 18 év and over
- People
- 20 worldwide
- Run by
- MedSIR
See details and how to joinNCT06315010 · EU 2023-508112-35-00 - 3. fázisTaking peopleRoll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
- Where
- Barcelona, Girona, Madrid, Marbella, Santiago De Compostela, Valencia
- Életkor
- 18 év and over
- People
- 87 worldwide
- Run by
- Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00 - 1. fázisTaking peopleOpen-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- Where
- Barcelona, Horta-Guinardó, Madrid
- Életkor
- 18 év and over
- People
- 350 worldwide
- Run by
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06343402 - 1. fázisTaking peopleA Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Where
- Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Seville, Valencia
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT04913285 - 1/2. fázisTaking peopleStudy of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
- Where
- Barcelona, Logroño, Madrid
- Életkor
- 18 év and over
- People
- 171 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT06567015 · EU 2023-510203-21-00 - 3. fázisTaking peopleStudy of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- A Coruña, Badalona, Barcelona, Córdoba, Girona, Jaén, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Málaga, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 355 worldwide
- Run by
- Gilead Sciences Inc.
See details and how to join2024-515884-69-00 - 2. fázisTaking peopleLuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor
- Where
- A Coruña, Badalona, Madrid
- Életkor
- 18 év and over
- People
- 36 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT04939610 · EU 2023-508995-12-01 - 1/2. fázisTaking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Barcelona, Madrid
- Életkor
- 18 év to 100 év
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - 3. fázisFut, nem toborozPhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Where
- A Coruña, Barcelona, Granada, Madrid, Majadahonda, Valencia
- Életkor
- 18 év and over
- People
- 582 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06350097 · EU 2023-509883-89-00 - 1/2. fázisTaking peopleA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Where
- Barcelona, Córdoba, Málaga, Sevilla, Torrejón de Ardoz, Valencia
- Életkor
- 18 év and over
- People
- 594 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06892548 · EU 2024-520238-31-01 - 1. fázisTaking peopleStudy of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
- Where
- Barcelona, Madrid, Málaga, Valencia
- Életkor
- 18 év to 99 év
- People
- 160 worldwide
- Run by
- Amgen
See details and how to joinNCT07531095 · EU 2025-522888-15-00 - 1. fázisTaking peopleA Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of VVD130037, in Participants With Advanced Solid Tumors
- Where
- Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Valencia
- Életkor
- 18 év and over
- People
- 65
- Run by
- Vividion Therapeutics Inc.
See details and how to joinNCT05954312 · EU 2023-506199-28-00 - 3. fázisTaking peopleStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Where
- Barcelona, Málaga, Oviedo, Palma, Valencia
- Életkor
- 18 év and over
- People
- 36 worldwide
- Run by
- Arrivent Biopharma Inc.
See details and how to join2025-522151-26-00 - 1/2. fázisTaking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Badalona, Barcelona, Madrid, Málaga, Pamplona
- Életkor
- 18 év and over
- People
- 1109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - 2. fázisNot yet taking people in SpanyolországA trial to learn how safe newer immunotherapy drugs are and how well they work with or without other anti-cancer drugs in adults with advanced, unresectable non-small cell lung cancer
- Where
- Barcelona, Madrid, Málaga, Vigo
- Életkor
- 18 év and over
- People
- 11 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-523599-21-00